{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T02:18:02Z","timestamp":1790907482498,"version":"4.1.0"},"reference-count":75,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T00:00:00Z","timestamp":1676505600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CBM"],"published-print":{"date-parts":[[2023,2,16]]},"abstract":"<jats:p>BACKGROUND: Programmed death ligand 1 (PD-L1) is the target of immune checkpoint inhibitor therapies in a growing number of tumor types, but a unanimous picture on PD-L1 expression across cancer types is lacking. MATERIALS AND METHODS: We analyzed immunohistochemical PD-L1 expression in 11,838 samples from 118 human tumor types and its relationship with tumor infiltrating CD8 positive lymphocytes. RESULTS: At a cut-off level of 10% positive tumor cells, PD-L1 positivity was seen in 85 of 118 (72%) tumor types, including thymoma (100% positive), Hodgkin\u2019s lymphoma (93%), anaplastic thyroid carcinoma (76%), Kaposi sarcoma (71%), sarcomatoid urothelial carcinoma (71%), and squamous cell carcinoma of the penis (67%), cervix (65%), floor of the mouth (61%), the lung (53%), and pharynx (50%). In immune cells, PD-L1 positivity was detectable in 103 (87%) tumor types, including tumors of haematopoetic and lymphoid tissues (75% to 100%), Warthin tumors of the parotid glands (95%) and Merkel cell carcinoma (82%). PD-L1 positivity in tumor cells was significantly correlated with the number of intratumoral CD8 positive lymphocytes across all tumor types as well as in individual tumor types, including serous carcinoma of the ovary, invasive breast carcinoma of no special type, intestinal gastric adenocarcinoma, and liposarcoma (p&lt; 0.0001 each). CONCLUSIONS: PD-L1 expression in tumor and inflammatory cells is found in a wide range of human tumor types. Higher rates of tumor infiltrating CD8 positive lymphocytes in PD-L1 positive than in PD-L1 negative cancers suggest that the antitumor immune response may trigger tumoral PD-L1 expression.<\/jats:p>","DOI":"10.3233\/cbm-220030","type":"journal-article","created":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T11:39:00Z","timestamp":1673955540000},"page":"177-191","source":"Crossref","is-referenced-by-count":15,"title":["PD-L1 expression and CD8 positive lymphocytes in human neoplasms: A tissue microarray study on 11,838 tumor samples"],"prefix":"10.1177","volume":"36","author":[{"given":"Katharina","family":"M\u00f6ller","sequence":"first","affiliation":[{"name":"Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"Kn\u00f6ll","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Bady","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max Jonathan","family":"Schmerder","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian Dwertmann","family":"Rico","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Kluth","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Hube-Magg","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niclas C.","family":"Blessin","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Mandelkow","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Lennartz","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Menz","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas M.","family":"Luebke","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris","family":"H\u00f6flmayer","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Fraune","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Bernreuther","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Lebok","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ria","family":"Uhlig","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrina","family":"Contreras","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f6ren","family":"Weidemann","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Gorbokon","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Jacobsen","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Till S.","family":"Clauditz","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Steurer","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eike","family":"Burandt","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Minner","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Sauter","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Simon","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas H.","family":"Marx","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"},{"name":"Department of Pathology, Academic Hospital Fuerth, Fuerth, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Till","family":"Krech","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"},{"name":"Institute of Pathology, Clinical Center Osnabrueck, Osnabrueck, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/CBM-220030_ref1","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1007\/s10147-019-01548-1","article-title":"Combination therapy with PD-1 or PD-L1 inhibitors for cancer","volume":"25","author":"Hayashi","year":"2020","journal-title":"Int J Clin Oncol"},{"key":"10.3233\/CBM-220030_ref2","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.2174\/1389450121666200123124642","article-title":"Status of Programmed Death Ligand 1 (PD-L1) by Immunohistochemistry and Scoring Algorithms","volume":"21","author":"Giunchi","year":"2020","journal-title":"Curr Drug Targets"},{"key":"10.3233\/CBM-220030_ref3","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3892\/ijo.2020.5062","article-title":"High expression of immune checkpoints is associated with the TIL load, mutation rate and patient survival in colorectal cancer","volume":"57","author":"Kitsou","year":"2020","journal-title":"Int J Oncol"},{"key":"10.3233\/CBM-220030_ref4","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/SLA.0000000000002616","article-title":"PD-L1 Expression, Tumor-infiltrating Lymphocytes, and Clinical Outcome in Patients With Surgically Resected Esophageal Cancer","volume":"269","author":"Yagi","year":"2019","journal-title":"Ann Surg"},{"key":"10.3233\/CBM-220030_ref5","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.ygyno.2016.03.008","article-title":"PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer","volume":"141","author":"Webb","year":"2016","journal-title":"Gynecol Oncol"},{"key":"10.3233\/CBM-220030_ref6","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.humpath.2015.09.003","article-title":"PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas","volume":"47","author":"Cimino-Mathews","year":"2016","journal-title":"Hum Pathol"},{"key":"10.3233\/CBM-220030_ref7","doi-asserted-by":"crossref","first-page":"10284","DOI":"10.18632\/oncotarget.22888","article-title":"Comprehensive immunohistochemical analysis of PD-L1 shows scarce expression in castration-resistant prostate cancer","volume":"9","author":"Fankhauser","year":"2018","journal-title":"Oncotarget"},{"key":"10.3233\/CBM-220030_ref8","doi-asserted-by":"crossref","first-page":"26789","DOI":"10.18632\/oncotarget.15817","article-title":"The prognostic role of immune checkpoint markers programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) in a large, multicenter prostate cancer cohort","volume":"8","author":"Ness","year":"2017","journal-title":"Oncotarget"},{"key":"10.3233\/CBM-220030_ref9","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1007\/s12253-020-00874-4","article-title":"Prognostic Role of Immune Markers in Triple Negative Breast Carcinoma","volume":"26","author":"Sahin Ozkan","year":"2020","journal-title":"Pathol Oncol Res"},{"key":"10.3233\/CBM-220030_ref10","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1093\/annonc\/mdv192","article-title":"PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes","volume":"26","author":"Ali","year":"2015","journal-title":"Ann Oncol"},{"key":"10.3233\/CBM-220030_ref11","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1007\/s00432-019-02942-y","article-title":"PD-L1 is a double-edged sword in colorectal cancer: the prognostic value of PD-L1 depends on the cell type expressing PD-L1","volume":"145","author":"Ho","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.3233\/CBM-220030_ref12","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1136\/gutjnl-2016-311421","article-title":"Tumour CD274 (PD-L1) expression and T cells in colorectal cancer","volume":"66","author":"Masugi","year":"2017","journal-title":"Gut"},{"key":"10.3233\/CBM-220030_ref13","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.oraloncology.2019.03.012","article-title":"Significant association of PD-L1 expression with human papillomavirus positivity and its prognostic impact in oropharyngeal cancer","volume":"92","author":"Hong","year":"2019","journal-title":"Oral Oncol"},{"key":"10.3233\/CBM-220030_ref14","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1002\/cam4.1108","article-title":"Comparative molecular profiling of HPV-induced squamous cell carcinomas","volume":"6","author":"Koncar","year":"2017","journal-title":"Cancer Med"},{"key":"10.3233\/CBM-220030_ref15","doi-asserted-by":"crossref","first-page":"6769","DOI":"10.1038\/s41598-019-43293-5","article-title":"Prognostic role of ARID1A negative expression in gastric cancer","volume":"9","author":"Ashizawa","year":"2019","journal-title":"Sci Rep"},{"key":"10.3233\/CBM-220030_ref16","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s10147-014-0701-7","article-title":"Expression of costimulatory molecules B7-H1, B7-H4 and Foxp3+ Tregs in gastric cancer and its clinical significance","volume":"20","author":"Geng","year":"2015","journal-title":"Int J Clin Oncol"},{"key":"10.3233\/CBM-220030_ref17","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.3389\/fonc.2020.01161","article-title":"Immunohistochemistry and Radiomic Features for Survival Prediction in Small Cell Lung Cancer","volume":"10","author":"Gkika","year":"2020","journal-title":"Front Oncol"},{"key":"10.3233\/CBM-220030_ref18","doi-asserted-by":"crossref","first-page":"6475","DOI":"10.2147\/OTT.S252031","article-title":"Expression of PD-1 and PD-L1 on Tumor-Infiltrating Lymphocytes Predicts Prognosis in Patients with Small-Cell Lung Cancer","volume":"13","author":"Sun","year":"2020","journal-title":"Onco Targets Ther"},{"key":"10.3233\/CBM-220030_ref19","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1097\/PAS.0000000000000653","article-title":"Comprehensive Immunohistochemical Study of Programmed Cell Death Ligand 1 (PD-L1): Analysis in 5536 Cases Revealed Consistent Expression in Trophoblastic Tumors","volume":"40","author":"Inaguma","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"10.3233\/CBM-220030_ref20","first-page":"3063","article-title":"The expression of PD-L1 APE1 and P53 in hepatocellular carcinoma and its relationship to clinical pathology","volume":"19","author":"Kan","year":"2015","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.3233\/CBM-220030_ref21","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/ajco.12788","article-title":"PD-L1 expression associated with worse survival outcome in malignant pleural mesothelioma","volume":"14","author":"Nguyen","year":"2018","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.3233\/CBM-220030_ref22","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.humpath.2016.01.010","article-title":"Immune biomarkers PD-1\/PD-L1 and TLR3 in malignant pleural mesotheliomas","volume":"52","author":"Combaz-Lair","year":"2016","journal-title":"Hum Pathol"},{"key":"10.3233\/CBM-220030_ref23","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.anndiagpath.2019.05.005","article-title":"Expression of programmed death ligand (PD-L1) in different tumors. Comparison of several current available antibody clones and antibody profiling","volume":"41","author":"Kintsler","year":"2019","journal-title":"Ann Diagn Pathol"},{"key":"10.3233\/CBM-220030_ref24","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1158\/1055-9965.EPI-14-0654","article-title":"Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type","volume":"23","author":"Gatalica","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.3233\/CBM-220030_ref25","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.pathol.2017.05.003","article-title":"PD-1 and PD-L1 expression in bone and soft tissue sarcomas","volume":"49","author":"Torabi","year":"2017","journal-title":"Pathology"},{"key":"10.3233\/CBM-220030_ref26","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1186\/s12967-018-1658-5","article-title":"Status of programmed death-ligand 1 expression in sarcomas","volume":"16","author":"Park","year":"2018","journal-title":"J Transl Med"},{"key":"10.3233\/CBM-220030_ref27","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1097\/DAD.0000000000001843","article-title":"Immune Checkpoint Markers in Superficial Angiosarcomas: PD-L1, PD-1, CD8, LAG-3, and Tumor-Infiltrating Lymphocytes","volume":"43","author":"Googe","year":"2021","journal-title":"Am J Dermatopathol"},{"key":"10.3233\/CBM-220030_ref28","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/978-1-4939-3204-7_3","article-title":"Tissue Microarrays","volume":"1381","author":"Dancau","year":"2016","journal-title":"Methods Mol Biol"},{"key":"10.3233\/CBM-220030_ref29","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/nm0798-844","article-title":"Tissue microarrays for high-throughput molecular profiling of tumor specimens","volume":"4","author":"Kononen","year":"1998","journal-title":"Nat Med"},{"key":"10.3233\/CBM-220030_ref30","doi-asserted-by":"crossref","unstructured":"N.C. Blessin, R. Abu-Hashem, T. Mandelkow, W. Li, R. Simon, C. Hube-Magg, C. M\u00f6ller-Koop, M. Witt, F. B\u00fcscheck, C. Fraune, A.M. Luebke, K. M\u00f6ller, F. Jacobsen, F. Lutz, M. Lennartz, S. Steurer, G. Sauter, D. H\u00f6flmayer, M.C. Tsourlakis, A. Hinsch, E. Burandt, W. Wilczak, S. Minner and T. Clauditz, Prevalance of proliferating CD8+ cells in normal lymphatic tissues, inflammation and cancer, Journal of Translational Medicine (submitted) (2020).","DOI":"10.18632\/aging.203113"},{"key":"10.3233\/CBM-220030_ref31","unstructured":"JMP\u00aeV, SAS Institute Inc, Cary, NC, https:\/\/www.jmp.com (2019)."},{"key":"10.3233\/CBM-220030_ref32","unstructured":"R-Core-Team, R: A language and environment for statistical computing, V. R Foundation for Statistical Computing, Austria ed. eds., https:\/\/www.R-project.org\/ (2019)."},{"key":"10.3233\/CBM-220030_ref33","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/517109a","article-title":"Programming tools: Adventures with R","volume":"517","author":"Tippmann","year":"2015","journal-title":"Nature"},{"key":"10.3233\/CBM-220030_ref34","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1200\/JCO.2017.74.7642","article-title":"Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer","volume":"35","author":"Buttner","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.3233\/CBM-220030_ref35","doi-asserted-by":"crossref","first-page":"198","DOI":"10.3389\/fmed.2020.00198","article-title":"Association of Programmed Death 1 Protein Ligand (PD-L1) Expression With Prognosis in Merkel Cell Carcinoma","volume":"7","author":"Hanna","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"10.3233\/CBM-220030_ref36","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1007\/s00432-020-03242-6","article-title":"PD-L1 and IDO1 expression and tumor-infiltrating lymphocytes in osteosarcoma patients: comparative study of primary and metastatic lesions","volume":"146","author":"Toda","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.3233\/CBM-220030_ref37","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/his.13230","article-title":"CD70 and PD-L1 in anaplastic thyroid cancer\u00a0\u2013 promising targets for immunotherapy","volume":"71","author":"Zwaenepoel","year":"2017","journal-title":"Histopathology"},{"key":"10.3233\/CBM-220030_ref38","doi-asserted-by":"crossref","unstructured":"I. Calik, M. Calik, G. Turken, I.H. Ozercan, A.F. Dagli, G. Artas and B. Sarikaya, Intratumoral Cytotoxic T-Lymphocyte Density and PD-L1 Expression Are Prognostic Biomarkers for Patients with Colorectal Cancer, Medicina (Kaunas) 55 (2019).","DOI":"10.3390\/medicina55110723"},{"key":"10.3233\/CBM-220030_ref39","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s12885-019-5345-6","article-title":"Programmed Death Ligand-1 expression in stage II colon cancer\u00a0\u2013 experiences from a nationwide populationbased cohort","volume":"19","author":"Eriksen","year":"2019","journal-title":"BMC Cancer"},{"key":"10.3233\/CBM-220030_ref40","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1136\/gutjnl-2015-310839","article-title":"Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma","volume":"66","author":"Thompson","year":"2017","journal-title":"Gut"},{"key":"10.3233\/CBM-220030_ref41","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/modpathol.2016.202","article-title":"Overexpression and gene amplification of PD-L1 in cancer cells and PD-L1(+) immune cells in Epstein-Barr virus-associated gastric cancer: the prognostic implications","volume":"30","author":"Saito","year":"2017","journal-title":"Mod Pathol"},{"key":"10.3233\/CBM-220030_ref42","doi-asserted-by":"crossref","first-page":"184","DOI":"10.4274\/balkanmedj.galenos.2018.2018.0392","article-title":"Programmed Death-Ligand-1 Expression in Non-Small Cell Lung Cancer and Prognosis","volume":"36","author":"Sahin","year":"2019","journal-title":"Balkan Med J"},{"key":"10.3233\/CBM-220030_ref43","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejca.2015.11.020","article-title":"Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy","volume":"55","author":"Tokito","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.3233\/CBM-220030_ref44","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1038\/s41379-019-0307-8","article-title":"A comparability study of immunohistochemical assays for PD-L1 expression in hepatocellular carcinoma","volume":"32","author":"Shi","year":"2019","journal-title":"Mod Pathol"},{"key":"10.3233\/CBM-220030_ref45","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/s41416-019-0466-x","article-title":"Clinical implications of heterogeneity in PD-L1 immunohistochemical detection in hepatocellular carcinoma: the Blueprint-HCC study","volume":"120","author":"Pinato","year":"2019","journal-title":"Br J Cancer"},{"key":"10.3233\/CBM-220030_ref46","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1158\/1078-0432.CCR-16-2375","article-title":"Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cutoffs in Non-Small Cell Lung Cancer","volume":"23","author":"Ratcliffe","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.3233\/CBM-220030_ref47","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41379-019-0327-4","article-title":"\u201cInterchangeability\u201d of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy","volume":"33","author":"Torlakovic","year":"2020","journal-title":"Mod Pathol"},{"key":"10.3233\/CBM-220030_ref48","unstructured":"Q.H. Zhou, K.W. Li, X. Chen, H.X. He, S.M. Peng, S.R. Peng, Q. Wang, Z.A. Li, Y.R. Tao, W.L. Cai, R.Y. Liu and H. Huang, HHLA2 and PD-L1 co-expression predicts poor prognosis in patients with clear cell renal cell carcinoma,"},{"key":"10.3233\/CBM-220030_ref49","doi-asserted-by":"crossref","first-page":"8584","DOI":"10.18632\/oncotarget.24196","article-title":"PD-L1 expression in colorectal cancer defines three subsets of tumor immune microenvironments","volume":"9","author":"Valentini","year":"2018","journal-title":"Oncotarget"},{"key":"10.3233\/CBM-220030_ref50","doi-asserted-by":"crossref","first-page":"e0136023","DOI":"10.1371\/journal.pone.0136023","article-title":"PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups","volume":"10","author":"Schmidt","year":"2015","journal-title":"PLoS One"},{"key":"10.3233\/CBM-220030_ref51","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1016\/j.ejca.2015.08.013","article-title":"Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: Comparison of sarcomatous and carcinomatous areas","volume":"51","author":"Kim","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.3233\/CBM-220030_ref52","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.18632\/oncotarget.26705","article-title":"POLE Score: a comprehensive profiling of programmed death 1 ligand 1 expression in pancreatic ductal adenocarcinoma","volume":"10","author":"Rahn","year":"2019","journal-title":"Oncotarget"},{"key":"10.3233\/CBM-220030_ref53","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1038\/modpathol.3800208","article-title":"Influence of slide aging on results of translational research studies using immunohistochemistry","volume":"17","author":"Mirlacher","year":"2004","journal-title":"Mod Pathol"},{"key":"10.3233\/CBM-220030_ref54","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1093\/jnci\/89.8.585","article-title":"Re: loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer","volume":"89","author":"Manne","year":"1997","journal-title":"J Natl Cancer Inst"},{"key":"10.3233\/CBM-220030_ref55","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1093\/jnci\/88.15.1054","article-title":"Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer","volume":"88","author":"Jacobs","year":"1996","journal-title":"J Natl Cancer Inst"},{"key":"10.3233\/CBM-220030_ref56","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1016\/S0002-9440(10)63075-1","article-title":"Tissue microarrays for rapid linking of molecular changes to clinical endpoints","volume":"159","author":"Torhorst","year":"2001","journal-title":"Am J Pathol"},{"key":"10.3233\/CBM-220030_ref57","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/00000478-200203000-00004","article-title":"Tissue microarray sampling strategy for prostate cancer biomarker analysis","volume":"26","author":"Rubin","year":"2002","journal-title":"Am J Surg Pathol"},{"key":"10.3233\/CBM-220030_ref58","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0002-9440(10)64075-8","article-title":"Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors","volume":"158","author":"Hoos","year":"2001","journal-title":"Am J Pathol"},{"key":"10.3233\/CBM-220030_ref59","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1038\/labinvest.3780204","article-title":"Validation of tissue microarray technology in breast carcinoma","volume":"80","author":"Camp","year":"2000","journal-title":"Lab Invest"},{"key":"10.3233\/CBM-220030_ref60","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ccell.2019.06.008","article-title":"Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1\/PD-L1 Therapeutic Efficacy","volume":"36","author":"Lee","year":"2019","journal-title":"Cancer Cell"},{"key":"10.3233\/CBM-220030_ref61","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1634\/theoncologist.2017-0096","article-title":"Exceptional Response with Immunotherapy in a Patient with Anaplastic Thyroid Cancer","volume":"22","author":"Kollipara","year":"2017","journal-title":"Oncologist"},{"key":"10.3233\/CBM-220030_ref62","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1055\/s-0041-1729443","article-title":"Real-World Experience of Immunotherapy from India in Recurrent Squamous Cell Carcinoma of Head and Neck Cancer","volume":"10","author":"Abbas","year":"2021","journal-title":"South Asian J Cancer"},{"key":"10.3233\/CBM-220030_ref63","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.2147\/CMAR.S249393","article-title":"Efficacy of Nivolumab for Head and Neck Cancer Patients with Primary Sites and Histological Subtypes Excluded from the CheckMate-141 Trial","volume":"12","author":"Sato","year":"2020","journal-title":"Cancer Manag Res"},{"key":"10.3233\/CBM-220030_ref64","doi-asserted-by":"crossref","first-page":"104492","DOI":"10.1016\/j.oraloncology.2019.104492","article-title":"Management of recurrent and metastatic oral cavity cancer: Raising the bar a step higher","volume":"101","author":"Szturz","year":"2020","journal-title":"Oral Oncol"},{"key":"10.3233\/CBM-220030_ref65","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.oraloncology.2018.04.008","article-title":"Nivolumab vs investigator\u2019s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression","volume":"81","author":"Ferris","year":"2018","journal-title":"Oral Oncol"},{"key":"10.3233\/CBM-220030_ref66","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1001\/jamaoncol.2020.2955","article-title":"Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial","volume":"6","author":"Schoenfeld","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.3233\/CBM-220030_ref67","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s10388-021-00850-0","article-title":"Five-year follow-up of nivolumab treatment in Japanese patients with esophageal squamous-cell carcinoma (ATTRACTION-1\/ONO-4538-07)","volume":"18","author":"Satoh","year":"2021","journal-title":"Esophagus"},{"key":"10.3233\/CBM-220030_ref68","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s10388-020-00794-x","article-title":"Nivolumab versus chemotherapy in Japanese patients with advanced esophageal squamous cell carcinoma: a subgroup analysis of a multicenter, randomized, open-label, phase 3 trial (ATTRACTION-3)","volume":"18","author":"Takahashi","year":"2021","journal-title":"Esophagus"},{"key":"10.3233\/CBM-220030_ref69","doi-asserted-by":"crossref","unstructured":"A. Wessely, T. Steeb, U. Leiter, C. Garbe, C. Berking and M.V. Heppt, Immune Checkpoint Blockade in Advanced Cutaneous Squamous Cell Carcinoma: What Do We Currently Know in 2020?,","DOI":"10.3390\/ijms21239300"},{"key":"10.3233\/CBM-220030_ref70","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1136\/ijgc-2019-000880","article-title":"A randomized phase III trial of platinum chemotherapy plus paclitaxel with bevacizumab and atezolizumab versus platinum chemotherapy plus paclitaxel and bevacizumab in metastatic (stage IVB), persistent, or recurrent carcinoma of the cervix: the BEATcc study (ENGOT-Cx10\/GEICO 68-C\/JGOG1084\/GOG-3030)","volume":"30","author":"Grau","year":"2020","journal-title":"Int J Gynecol Cancer"},{"key":"10.3233\/CBM-220030_ref71","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s11912-018-0712-z","article-title":"Immunotherapy in Prostate Cancer: Teaching an Old Dog New Tricks","volume":"20","author":"Comiskey","year":"2018","journal-title":"Curr Oncol Rep"},{"key":"10.3233\/CBM-220030_ref72","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1158\/0008-5472.CAN-18-3208","article-title":"Anti-PD-L1 Treatment Results in Functional Remodeling of the Macrophage Compartment","volume":"79","author":"Xiong","year":"2019","journal-title":"Cancer Res"},{"key":"10.3233\/CBM-220030_ref73","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1038\/s41379-020-0606-0","article-title":"Clinical and pathologic features associated with PD-L1 (SP142) expression in stromal tumor-infiltrating immune cells of triple-negative breast carcinoma","volume":"33","author":"Hoda","year":"2020","journal-title":"Mod Pathol"},{"key":"10.3233\/CBM-220030_ref74","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N Engl J Med"},{"key":"10.3233\/CBM-220030_ref75","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/s41379-020-00664-y","article-title":"A pan-cancer analysis of PD-L1 immunohistochemistry and gene amplification, tumor mutation burden and microsatellite instability in 48,782 cases","volume":"34","author":"Huang","year":"2021","journal-title":"Mod Pathol"}],"container-title":["Cancer Biomarkers"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/CBM-220030","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:08:55Z","timestamp":1777385335000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/CBM-220030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,16]]},"references-count":75,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.3233\/cbm-220030","relation":{},"ISSN":["1875-8592","1574-0153"],"issn-type":[{"value":"1875-8592","type":"electronic"},{"value":"1574-0153","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2,16]]}}}